nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP2B6—malignant glioma	0.359	0.54	CbGaD
Fluvoxamine—SLC6A3—malignant glioma	0.306	0.46	CbGaD
Fluvoxamine—CYP1A2—Carmustine—malignant glioma	0.0738	0.57	CbGbCtD
Fluvoxamine—CYP3A4—Temozolomide—malignant glioma	0.0558	0.431	CbGbCtD
Fluvoxamine—Hemiplegia—Carmustine—malignant glioma	0.00224	0.0174	CcSEcCtD
Fluvoxamine—Hemiplegia—Temozolomide—malignant glioma	0.00216	0.0169	CcSEcCtD
Fluvoxamine—Hyperacusis—Temozolomide—malignant glioma	0.00207	0.0162	CcSEcCtD
Fluvoxamine—Paranoid reaction—Carmustine—malignant glioma	0.00188	0.0147	CcSEcCtD
Fluvoxamine—Tongue discolouration—Temozolomide—malignant glioma	0.0016	0.0125	CcSEcCtD
Fluvoxamine—Faecal incontinence—Carmustine—malignant glioma	0.00158	0.0123	CcSEcCtD
Fluvoxamine—Faecal incontinence—Temozolomide—malignant glioma	0.00153	0.0119	CcSEcCtD
Fluvoxamine—Haemorrhoids—Temozolomide—malignant glioma	0.00131	0.0102	CcSEcCtD
Fluvoxamine—Myasthenia—Carmustine—malignant glioma	0.00127	0.00991	CcSEcCtD
Fluvoxamine—Embolism—Temozolomide—malignant glioma	0.0012	0.00938	CcSEcCtD
Fluvoxamine—Tooth disorder—Temozolomide—malignant glioma	0.00119	0.00928	CcSEcCtD
Fluvoxamine—Parosmia—Temozolomide—malignant glioma	0.00119	0.00928	CcSEcCtD
Fluvoxamine—Hypokinesia—Carmustine—malignant glioma	0.00118	0.00923	CcSEcCtD
Fluvoxamine—Paranoia—Carmustine—malignant glioma	0.00117	0.00914	CcSEcCtD
Fluvoxamine—Interstitial lung disease—Carmustine—malignant glioma	0.00113	0.0088	CcSEcCtD
Fluvoxamine—Myopathy—Temozolomide—malignant glioma	0.0011	0.00859	CcSEcCtD
Fluvoxamine—Interstitial lung disease—Temozolomide—malignant glioma	0.00109	0.00851	CcSEcCtD
Fluvoxamine—Apathy—Temozolomide—malignant glioma	0.00108	0.00843	CcSEcCtD
Fluvoxamine—Flat affect—Temozolomide—malignant glioma	0.00107	0.00835	CcSEcCtD
Fluvoxamine—Stupor—Carmustine—malignant glioma	0.00107	0.00835	CcSEcCtD
Fluvoxamine—Scotoma—Carmustine—malignant glioma	0.00105	0.00821	CcSEcCtD
Fluvoxamine—Menorrhagia—Temozolomide—malignant glioma	0.00104	0.00814	CcSEcCtD
Fluvoxamine—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00104	0.00814	CcSEcCtD
Fluvoxamine—Herpes zoster—Temozolomide—malignant glioma	0.00102	0.008	CcSEcCtD
Fluvoxamine—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00102	0.008	CcSEcCtD
Fluvoxamine—Scotoma—Temozolomide—malignant glioma	0.00102	0.00793	CcSEcCtD
Fluvoxamine—Abscess—Carmustine—malignant glioma	0.00101	0.00788	CcSEcCtD
Fluvoxamine—Otitis media—Temozolomide—malignant glioma	0.000991	0.00773	CcSEcCtD
Fluvoxamine—Hyperaesthesia—Temozolomide—malignant glioma	0.000983	0.00767	CcSEcCtD
Fluvoxamine—SLC6A3—telencephalic ventricle—malignant glioma	0.000969	0.163	CbGeAlD
Fluvoxamine—Endocrine disorder—Temozolomide—malignant glioma	0.000931	0.00726	CcSEcCtD
Fluvoxamine—Accidental injury—Carmustine—malignant glioma	0.000902	0.00704	CcSEcCtD
Fluvoxamine—Breast pain—Temozolomide—malignant glioma	0.000884	0.0069	CcSEcCtD
Fluvoxamine—Amenorrhoea—Temozolomide—malignant glioma	0.000878	0.00685	CcSEcCtD
Fluvoxamine—Thinking abnormal—Carmustine—malignant glioma	0.000872	0.00681	CcSEcCtD
Fluvoxamine—Drug interaction—Carmustine—malignant glioma	0.000861	0.00672	CcSEcCtD
Fluvoxamine—Viral infection—Temozolomide—malignant glioma	0.000854	0.00667	CcSEcCtD
Fluvoxamine—Leukocytosis—Carmustine—malignant glioma	0.00085	0.00663	CcSEcCtD
Fluvoxamine—Herpes simplex—Temozolomide—malignant glioma	0.000837	0.00653	CcSEcCtD
Fluvoxamine—Gait disturbance—Carmustine—malignant glioma	0.000818	0.00638	CcSEcCtD
Fluvoxamine—Coordination abnormal—Carmustine—malignant glioma	0.000813	0.00635	CcSEcCtD
Fluvoxamine—Neck pain—Carmustine—malignant glioma	0.000808	0.00631	CcSEcCtD
Fluvoxamine—Gait disturbance—Temozolomide—malignant glioma	0.000791	0.00617	CcSEcCtD
Fluvoxamine—Coordination abnormal—Temozolomide—malignant glioma	0.000786	0.00613	CcSEcCtD
Fluvoxamine—Vaginal inflammation—Temozolomide—malignant glioma	0.000772	0.00602	CcSEcCtD
Fluvoxamine—Depressed level of consciousness—Carmustine—malignant glioma	0.000771	0.00602	CcSEcCtD
Fluvoxamine—Urinary incontinence—Carmustine—malignant glioma	0.000771	0.00602	CcSEcCtD
Fluvoxamine—Neuropathy—Carmustine—malignant glioma	0.00075	0.00585	CcSEcCtD
Fluvoxamine—Urinary incontinence—Temozolomide—malignant glioma	0.000745	0.00581	CcSEcCtD
Fluvoxamine—Depressed level of consciousness—Temozolomide—malignant glioma	0.000745	0.00581	CcSEcCtD
Fluvoxamine—Coma—Carmustine—malignant glioma	0.00073	0.00569	CcSEcCtD
Fluvoxamine—Vaginal infection—Temozolomide—malignant glioma	0.000729	0.00568	CcSEcCtD
Fluvoxamine—Aplastic anaemia—Temozolomide—malignant glioma	0.000724	0.00565	CcSEcCtD
Fluvoxamine—Neuropathy—Temozolomide—malignant glioma	0.000724	0.00565	CcSEcCtD
Fluvoxamine—Neoplasm—Carmustine—malignant glioma	0.000722	0.00563	CcSEcCtD
Fluvoxamine—Dry eye—Temozolomide—malignant glioma	0.000713	0.00556	CcSEcCtD
Fluvoxamine—Neoplasm—Temozolomide—malignant glioma	0.000698	0.00544	CcSEcCtD
Fluvoxamine—Abnormal vision—Carmustine—malignant glioma	0.000696	0.00543	CcSEcCtD
Fluvoxamine—Mental disability—Carmustine—malignant glioma	0.000693	0.00541	CcSEcCtD
Fluvoxamine—Abnormal vision—Temozolomide—malignant glioma	0.000673	0.00525	CcSEcCtD
Fluvoxamine—Phlebitis—Carmustine—malignant glioma	0.000673	0.00525	CcSEcCtD
Fluvoxamine—Mental disability—Temozolomide—malignant glioma	0.00067	0.00523	CcSEcCtD
Fluvoxamine—Diabetes mellitus—Carmustine—malignant glioma	0.000666	0.0052	CcSEcCtD
Fluvoxamine—Ear pain—Temozolomide—malignant glioma	0.000657	0.00512	CcSEcCtD
Fluvoxamine—Eye pain—Carmustine—malignant glioma	0.000642	0.00501	CcSEcCtD
Fluvoxamine—Gastroenteritis—Temozolomide—malignant glioma	0.000632	0.00493	CcSEcCtD
Fluvoxamine—Injury—Carmustine—malignant glioma	0.000631	0.00492	CcSEcCtD
Fluvoxamine—Vascular purpura—Temozolomide—malignant glioma	0.000626	0.00489	CcSEcCtD
Fluvoxamine—Deafness—Temozolomide—malignant glioma	0.000626	0.00489	CcSEcCtD
Fluvoxamine—Eye pain—Temozolomide—malignant glioma	0.00062	0.00484	CcSEcCtD
Fluvoxamine—Amnesia—Carmustine—malignant glioma	0.000617	0.00481	CcSEcCtD
Fluvoxamine—Amnesia—Temozolomide—malignant glioma	0.000596	0.00465	CcSEcCtD
Fluvoxamine—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000594	0.00463	CcSEcCtD
Fluvoxamine—Thirst—Temozolomide—malignant glioma	0.000589	0.00459	CcSEcCtD
Fluvoxamine—Hyponatraemia—Carmustine—malignant glioma	0.000582	0.00454	CcSEcCtD
Fluvoxamine—Purpura—Temozolomide—malignant glioma	0.000581	0.00454	CcSEcCtD
Fluvoxamine—Diplopia—Carmustine—malignant glioma	0.00058	0.00452	CcSEcCtD
Fluvoxamine—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00058	0.00452	CcSEcCtD
Fluvoxamine—Diplopia—Temozolomide—malignant glioma	0.00056	0.00437	CcSEcCtD
Fluvoxamine—Face oedema—Carmustine—malignant glioma	0.00056	0.00437	CcSEcCtD
Fluvoxamine—Affect lability—Temozolomide—malignant glioma	0.000551	0.0043	CcSEcCtD
Fluvoxamine—Ataxia—Carmustine—malignant glioma	0.000545	0.00425	CcSEcCtD
Fluvoxamine—Face oedema—Temozolomide—malignant glioma	0.000541	0.00422	CcSEcCtD
Fluvoxamine—Liver function test abnormal—Carmustine—malignant glioma	0.000535	0.00418	CcSEcCtD
Fluvoxamine—Mood swings—Temozolomide—malignant glioma	0.000531	0.00414	CcSEcCtD
Fluvoxamine—Hypokalaemia—Carmustine—malignant glioma	0.000528	0.00412	CcSEcCtD
Fluvoxamine—Ataxia—Temozolomide—malignant glioma	0.000527	0.00411	CcSEcCtD
Fluvoxamine—Dehydration—Temozolomide—malignant glioma	0.000521	0.00407	CcSEcCtD
Fluvoxamine—Dry skin—Temozolomide—malignant glioma	0.000513	0.00401	CcSEcCtD
Fluvoxamine—Muscular weakness—Carmustine—malignant glioma	0.000511	0.00399	CcSEcCtD
Fluvoxamine—Hypokalaemia—Temozolomide—malignant glioma	0.00051	0.00398	CcSEcCtD
Fluvoxamine—Breast disorder—Temozolomide—malignant glioma	0.000506	0.00395	CcSEcCtD
Fluvoxamine—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000504	0.00394	CcSEcCtD
Fluvoxamine—Dysphagia—Carmustine—malignant glioma	0.000501	0.00391	CcSEcCtD
Fluvoxamine—Muscular weakness—Temozolomide—malignant glioma	0.000494	0.00386	CcSEcCtD
Fluvoxamine—Abdominal distension—Temozolomide—malignant glioma	0.000487	0.0038	CcSEcCtD
Fluvoxamine—Dysphagia—Temozolomide—malignant glioma	0.000484	0.00378	CcSEcCtD
Fluvoxamine—Sweating increased—Temozolomide—malignant glioma	0.000472	0.00368	CcSEcCtD
Fluvoxamine—Bronchitis—Temozolomide—malignant glioma	0.000466	0.00363	CcSEcCtD
Fluvoxamine—Dysuria—Temozolomide—malignant glioma	0.000453	0.00353	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Carmustine—malignant glioma	0.000452	0.00353	CcSEcCtD
Fluvoxamine—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00045	0.00351	CcSEcCtD
Fluvoxamine—Pneumonia—Carmustine—malignant glioma	0.000449	0.00351	CcSEcCtD
Fluvoxamine—Pollakiuria—Temozolomide—malignant glioma	0.000447	0.00349	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Temozolomide—malignant glioma	0.000446	0.00348	CcSEcCtD
Fluvoxamine—Depression—Carmustine—malignant glioma	0.000445	0.00348	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Temozolomide—malignant glioma	0.000442	0.00345	CcSEcCtD
Fluvoxamine—Weight increased—Temozolomide—malignant glioma	0.000441	0.00344	CcSEcCtD
Fluvoxamine—Renal failure—Carmustine—malignant glioma	0.000439	0.00343	CcSEcCtD
Fluvoxamine—Weight decreased—Temozolomide—malignant glioma	0.000438	0.00342	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Carmustine—malignant glioma	0.000438	0.00342	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Temozolomide—malignant glioma	0.000437	0.00341	CcSEcCtD
Fluvoxamine—Stomatitis—Carmustine—malignant glioma	0.000435	0.0034	CcSEcCtD
Fluvoxamine—Urinary tract infection—Carmustine—malignant glioma	0.000434	0.00339	CcSEcCtD
Fluvoxamine—Pneumonia—Temozolomide—malignant glioma	0.000434	0.00339	CcSEcCtD
Fluvoxamine—Depression—Temozolomide—malignant glioma	0.00043	0.00336	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000428	0.00334	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Temozolomide—malignant glioma	0.000423	0.0033	CcSEcCtD
Fluvoxamine—Stomatitis—Temozolomide—malignant glioma	0.000421	0.00328	CcSEcCtD
Fluvoxamine—Urinary tract infection—Temozolomide—malignant glioma	0.00042	0.00327	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Temozolomide—malignant glioma	0.000408	0.00319	CcSEcCtD
Fluvoxamine—Sinusitis—Temozolomide—malignant glioma	0.000405	0.00316	CcSEcCtD
Fluvoxamine—Haemoglobin—Carmustine—malignant glioma	0.000403	0.00315	CcSEcCtD
Fluvoxamine—Haemorrhage—Carmustine—malignant glioma	0.000401	0.00313	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Carmustine—malignant glioma	0.000399	0.00311	CcSEcCtD
Fluvoxamine—Hallucination—Carmustine—malignant glioma	0.000399	0.00311	CcSEcCtD
Fluvoxamine—Oedema peripheral—Carmustine—malignant glioma	0.000395	0.00308	CcSEcCtD
Fluvoxamine—Haemoglobin—Temozolomide—malignant glioma	0.000389	0.00304	CcSEcCtD
Fluvoxamine—Haemorrhage—Temozolomide—malignant glioma	0.000388	0.00302	CcSEcCtD
Fluvoxamine—Hepatitis—Temozolomide—malignant glioma	0.000388	0.00302	CcSEcCtD
Fluvoxamine—Visual impairment—Carmustine—malignant glioma	0.000386	0.00302	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Temozolomide—malignant glioma	0.000386	0.00301	CcSEcCtD
Fluvoxamine—Hallucination—Temozolomide—malignant glioma	0.000386	0.00301	CcSEcCtD
Fluvoxamine—Pharyngitis—Temozolomide—malignant glioma	0.000385	0.003	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Temozolomide—malignant glioma	0.000383	0.00299	CcSEcCtD
Fluvoxamine—Oedema peripheral—Temozolomide—malignant glioma	0.000382	0.00298	CcSEcCtD
Fluvoxamine—Urethral disorder—Temozolomide—malignant glioma	0.00038	0.00296	CcSEcCtD
Fluvoxamine—Eye disorder—Carmustine—malignant glioma	0.000375	0.00292	CcSEcCtD
Fluvoxamine—Visual impairment—Temozolomide—malignant glioma	0.000373	0.00291	CcSEcCtD
Fluvoxamine—Erythema multiforme—Temozolomide—malignant glioma	0.000366	0.00286	CcSEcCtD
Fluvoxamine—Eye disorder—Temozolomide—malignant glioma	0.000362	0.00283	CcSEcCtD
Fluvoxamine—Tinnitus—Temozolomide—malignant glioma	0.000361	0.00282	CcSEcCtD
Fluvoxamine—Cardiac disorder—Temozolomide—malignant glioma	0.00036	0.00281	CcSEcCtD
Fluvoxamine—Arrhythmia—Carmustine—malignant glioma	0.000358	0.0028	CcSEcCtD
Fluvoxamine—Alopecia—Carmustine—malignant glioma	0.000354	0.00277	CcSEcCtD
Fluvoxamine—Angiopathy—Temozolomide—malignant glioma	0.000352	0.00274	CcSEcCtD
Fluvoxamine—Mental disorder—Carmustine—malignant glioma	0.000351	0.00274	CcSEcCtD
Fluvoxamine—Malnutrition—Carmustine—malignant glioma	0.000349	0.00272	CcSEcCtD
Fluvoxamine—Chills—Temozolomide—malignant glioma	0.000348	0.00271	CcSEcCtD
Fluvoxamine—Alopecia—Temozolomide—malignant glioma	0.000342	0.00267	CcSEcCtD
Fluvoxamine—Mental disorder—Temozolomide—malignant glioma	0.000339	0.00265	CcSEcCtD
Fluvoxamine—Back pain—Carmustine—malignant glioma	0.000338	0.00263	CcSEcCtD
Fluvoxamine—Malnutrition—Temozolomide—malignant glioma	0.000337	0.00263	CcSEcCtD
Fluvoxamine—Dysgeusia—Temozolomide—malignant glioma	0.00033	0.00258	CcSEcCtD
Fluvoxamine—Vision blurred—Carmustine—malignant glioma	0.000329	0.00257	CcSEcCtD
Fluvoxamine—Tremor—Carmustine—malignant glioma	0.000327	0.00255	CcSEcCtD
Fluvoxamine—Back pain—Temozolomide—malignant glioma	0.000326	0.00255	CcSEcCtD
Fluvoxamine—Anaemia—Carmustine—malignant glioma	0.000323	0.00252	CcSEcCtD
Fluvoxamine—Agitation—Carmustine—malignant glioma	0.000321	0.0025	CcSEcCtD
Fluvoxamine—Vision blurred—Temozolomide—malignant glioma	0.000318	0.00248	CcSEcCtD
Fluvoxamine—Tremor—Temozolomide—malignant glioma	0.000316	0.00247	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Temozolomide—malignant glioma	0.000313	0.00244	CcSEcCtD
Fluvoxamine—Leukopenia—Carmustine—malignant glioma	0.000312	0.00244	CcSEcCtD
Fluvoxamine—Anaemia—Temozolomide—malignant glioma	0.000312	0.00243	CcSEcCtD
Fluvoxamine—Agitation—Temozolomide—malignant glioma	0.00031	0.00242	CcSEcCtD
Fluvoxamine—Angioedema—Temozolomide—malignant glioma	0.000308	0.00241	CcSEcCtD
Fluvoxamine—Malaise—Temozolomide—malignant glioma	0.000304	0.00237	CcSEcCtD
Fluvoxamine—Vertigo—Temozolomide—malignant glioma	0.000303	0.00237	CcSEcCtD
Fluvoxamine—Convulsion—Carmustine—malignant glioma	0.000302	0.00236	CcSEcCtD
Fluvoxamine—Leukopenia—Temozolomide—malignant glioma	0.000302	0.00236	CcSEcCtD
Fluvoxamine—Hypertension—Carmustine—malignant glioma	0.000301	0.00235	CcSEcCtD
Fluvoxamine—Palpitations—Temozolomide—malignant glioma	0.000298	0.00233	CcSEcCtD
Fluvoxamine—Myalgia—Carmustine—malignant glioma	0.000297	0.00232	CcSEcCtD
Fluvoxamine—Chest pain—Carmustine—malignant glioma	0.000297	0.00232	CcSEcCtD
Fluvoxamine—Anxiety—Carmustine—malignant glioma	0.000296	0.00231	CcSEcCtD
Fluvoxamine—Cough—Temozolomide—malignant glioma	0.000294	0.0023	CcSEcCtD
Fluvoxamine—Convulsion—Temozolomide—malignant glioma	0.000292	0.00228	CcSEcCtD
Fluvoxamine—Hypertension—Temozolomide—malignant glioma	0.000291	0.00227	CcSEcCtD
Fluvoxamine—Confusional state—Carmustine—malignant glioma	0.000287	0.00224	CcSEcCtD
Fluvoxamine—Myalgia—Temozolomide—malignant glioma	0.000287	0.00224	CcSEcCtD
Fluvoxamine—Arthralgia—Temozolomide—malignant glioma	0.000287	0.00224	CcSEcCtD
Fluvoxamine—Anxiety—Temozolomide—malignant glioma	0.000286	0.00223	CcSEcCtD
Fluvoxamine—Oedema—Carmustine—malignant glioma	0.000285	0.00222	CcSEcCtD
Fluvoxamine—Discomfort—Temozolomide—malignant glioma	0.000284	0.00221	CcSEcCtD
Fluvoxamine—Infection—Carmustine—malignant glioma	0.000283	0.00221	CcSEcCtD
Fluvoxamine—Dry mouth—Temozolomide—malignant glioma	0.000281	0.00219	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Carmustine—malignant glioma	0.000279	0.00218	CcSEcCtD
Fluvoxamine—Tachycardia—Carmustine—malignant glioma	0.000278	0.00217	CcSEcCtD
Fluvoxamine—Confusional state—Temozolomide—malignant glioma	0.000278	0.00217	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Temozolomide—malignant glioma	0.000275	0.00215	CcSEcCtD
Fluvoxamine—Oedema—Temozolomide—malignant glioma	0.000275	0.00215	CcSEcCtD
Fluvoxamine—Infection—Temozolomide—malignant glioma	0.000274	0.00213	CcSEcCtD
Fluvoxamine—Anorexia—Carmustine—malignant glioma	0.000272	0.00212	CcSEcCtD
Fluvoxamine—Nervous system disorder—Temozolomide—malignant glioma	0.00027	0.00211	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Temozolomide—malignant glioma	0.00027	0.0021	CcSEcCtD
Fluvoxamine—Hypotension—Carmustine—malignant glioma	0.000266	0.00208	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Temozolomide—malignant glioma	0.000266	0.00208	CcSEcCtD
Fluvoxamine—Anorexia—Temozolomide—malignant glioma	0.000262	0.00205	CcSEcCtD
Fluvoxamine—SLC6A3—brainstem—malignant glioma	0.000262	0.044	CbGeAlD
Fluvoxamine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00026	0.00203	CcSEcCtD
Fluvoxamine—Insomnia—Carmustine—malignant glioma	0.000258	0.00201	CcSEcCtD
Fluvoxamine—Paraesthesia—Carmustine—malignant glioma	0.000256	0.002	CcSEcCtD
Fluvoxamine—Dyspnoea—Carmustine—malignant glioma	0.000254	0.00198	CcSEcCtD
Fluvoxamine—Somnolence—Carmustine—malignant glioma	0.000253	0.00198	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000251	0.00196	CcSEcCtD
Fluvoxamine—Insomnia—Temozolomide—malignant glioma	0.000249	0.00194	CcSEcCtD
Fluvoxamine—Decreased appetite—Carmustine—malignant glioma	0.000248	0.00193	CcSEcCtD
Fluvoxamine—Paraesthesia—Temozolomide—malignant glioma	0.000247	0.00193	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Carmustine—malignant glioma	0.000246	0.00192	CcSEcCtD
Fluvoxamine—Dyspnoea—Temozolomide—malignant glioma	0.000245	0.00192	CcSEcCtD
Fluvoxamine—Somnolence—Temozolomide—malignant glioma	0.000245	0.00191	CcSEcCtD
Fluvoxamine—Pain—Carmustine—malignant glioma	0.000244	0.0019	CcSEcCtD
Fluvoxamine—Constipation—Carmustine—malignant glioma	0.000244	0.0019	CcSEcCtD
Fluvoxamine—Dyspepsia—Temozolomide—malignant glioma	0.000242	0.00189	CcSEcCtD
Fluvoxamine—SLC6A4—brainstem—malignant glioma	0.00024	0.0403	CbGeAlD
Fluvoxamine—Decreased appetite—Temozolomide—malignant glioma	0.000239	0.00187	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000238	0.00185	CcSEcCtD
Fluvoxamine—Fatigue—Temozolomide—malignant glioma	0.000237	0.00185	CcSEcCtD
Fluvoxamine—Pain—Temozolomide—malignant glioma	0.000235	0.00184	CcSEcCtD
Fluvoxamine—Constipation—Temozolomide—malignant glioma	0.000235	0.00184	CcSEcCtD
Fluvoxamine—Feeling abnormal—Carmustine—malignant glioma	0.000235	0.00183	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Carmustine—malignant glioma	0.000233	0.00182	CcSEcCtD
Fluvoxamine—SLC6A3—telencephalon—malignant glioma	0.000233	0.0391	CbGeAlD
Fluvoxamine—Feeling abnormal—Temozolomide—malignant glioma	0.000227	0.00177	CcSEcCtD
Fluvoxamine—Abdominal pain—Carmustine—malignant glioma	0.000225	0.00176	CcSEcCtD
Fluvoxamine—Body temperature increased—Carmustine—malignant glioma	0.000225	0.00176	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Temozolomide—malignant glioma	0.000225	0.00176	CcSEcCtD
Fluvoxamine—Urticaria—Temozolomide—malignant glioma	0.000219	0.00171	CcSEcCtD
Fluvoxamine—Abdominal pain—Temozolomide—malignant glioma	0.000218	0.0017	CcSEcCtD
Fluvoxamine—Body temperature increased—Temozolomide—malignant glioma	0.000218	0.0017	CcSEcCtD
Fluvoxamine—SLC6A4—telencephalon—malignant glioma	0.000213	0.0358	CbGeAlD
Fluvoxamine—SIGMAR1—telencephalon—malignant glioma	0.000212	0.0356	CbGeAlD
Fluvoxamine—Hypersensitivity—Carmustine—malignant glioma	0.00021	0.00164	CcSEcCtD
Fluvoxamine—Asthenia—Carmustine—malignant glioma	0.000204	0.0016	CcSEcCtD
Fluvoxamine—Hypersensitivity—Temozolomide—malignant glioma	0.000203	0.00158	CcSEcCtD
Fluvoxamine—Asthenia—Temozolomide—malignant glioma	0.000198	0.00154	CcSEcCtD
Fluvoxamine—Diarrhoea—Carmustine—malignant glioma	0.000195	0.00152	CcSEcCtD
Fluvoxamine—Pruritus—Temozolomide—malignant glioma	0.000195	0.00152	CcSEcCtD
Fluvoxamine—Dizziness—Carmustine—malignant glioma	0.000188	0.00147	CcSEcCtD
Fluvoxamine—Diarrhoea—Temozolomide—malignant glioma	0.000188	0.00147	CcSEcCtD
Fluvoxamine—Dizziness—Temozolomide—malignant glioma	0.000182	0.00142	CcSEcCtD
Fluvoxamine—Vomiting—Carmustine—malignant glioma	0.000181	0.00141	CcSEcCtD
Fluvoxamine—Rash—Carmustine—malignant glioma	0.00018	0.0014	CcSEcCtD
Fluvoxamine—Dermatitis—Carmustine—malignant glioma	0.000179	0.0014	CcSEcCtD
Fluvoxamine—Headache—Carmustine—malignant glioma	0.000178	0.00139	CcSEcCtD
Fluvoxamine—Vomiting—Temozolomide—malignant glioma	0.000175	0.00137	CcSEcCtD
Fluvoxamine—Rash—Temozolomide—malignant glioma	0.000174	0.00135	CcSEcCtD
Fluvoxamine—Dermatitis—Temozolomide—malignant glioma	0.000173	0.00135	CcSEcCtD
Fluvoxamine—Headache—Temozolomide—malignant glioma	0.000172	0.00135	CcSEcCtD
Fluvoxamine—Nausea—Carmustine—malignant glioma	0.000169	0.00132	CcSEcCtD
Fluvoxamine—SLC6A3—midbrain—malignant glioma	0.000167	0.0281	CbGeAlD
Fluvoxamine—SIGMAR1—medulla oblongata—malignant glioma	0.000166	0.0279	CbGeAlD
Fluvoxamine—Nausea—Temozolomide—malignant glioma	0.000164	0.00128	CcSEcCtD
Fluvoxamine—SLC6A3—spinal cord—malignant glioma	0.000163	0.0274	CbGeAlD
Fluvoxamine—SLC6A4—midbrain—malignant glioma	0.000153	0.0257	CbGeAlD
Fluvoxamine—ABCB1—blood vessel—malignant glioma	0.000152	0.0256	CbGeAlD
Fluvoxamine—SIGMAR1—midbrain—malignant glioma	0.000152	0.0255	CbGeAlD
Fluvoxamine—SLC6A4—spinal cord—malignant glioma	0.000149	0.0251	CbGeAlD
Fluvoxamine—SIGMAR1—spinal cord—malignant glioma	0.000148	0.0249	CbGeAlD
Fluvoxamine—SLC6A3—central nervous system—malignant glioma	0.000132	0.0222	CbGeAlD
Fluvoxamine—CYP2E1—telencephalon—malignant glioma	0.00013	0.0218	CbGeAlD
Fluvoxamine—SLC6A3—cerebellum—malignant glioma	0.000129	0.0217	CbGeAlD
Fluvoxamine—SLC6A4—central nervous system—malignant glioma	0.000121	0.0203	CbGeAlD
Fluvoxamine—SIGMAR1—cerebellum—malignant glioma	0.000118	0.0198	CbGeAlD
Fluvoxamine—CYP2D6—brainstem—malignant glioma	0.000116	0.0194	CbGeAlD
Fluvoxamine—SLC6A3—brain—malignant glioma	0.000105	0.0176	CbGeAlD
Fluvoxamine—CYP2D6—telencephalon—malignant glioma	0.000103	0.0173	CbGeAlD
Fluvoxamine—CYP2E1—medulla oblongata—malignant glioma	0.000102	0.0171	CbGeAlD
Fluvoxamine—SLC6A4—brain—malignant glioma	9.62e-05	0.0162	CbGeAlD
Fluvoxamine—SIGMAR1—brain—malignant glioma	9.55e-05	0.016	CbGeAlD
Fluvoxamine—CYP2E1—spinal cord—malignant glioma	9.09e-05	0.0153	CbGeAlD
Fluvoxamine—ABCB1—embryo—malignant glioma	9.09e-05	0.0153	CbGeAlD
Fluvoxamine—CYP1A1—central nervous system—malignant glioma	8.09e-05	0.0136	CbGeAlD
Fluvoxamine—ABCB1—retina—malignant glioma	8.04e-05	0.0135	CbGeAlD
Fluvoxamine—CYP2B6—central nervous system—malignant glioma	7.86e-05	0.0132	CbGeAlD
Fluvoxamine—ABCB1—telencephalon—malignant glioma	7.39e-05	0.0124	CbGeAlD
Fluvoxamine—CYP2E1—central nervous system—malignant glioma	7.38e-05	0.0124	CbGeAlD
Fluvoxamine—CYP2E1—cerebellum—malignant glioma	7.21e-05	0.0121	CbGeAlD
Fluvoxamine—CYP1A1—brain—malignant glioma	6.42e-05	0.0108	CbGeAlD
Fluvoxamine—CYP2B6—brain—malignant glioma	6.24e-05	0.0105	CbGeAlD
Fluvoxamine—CYP3A4—central nervous system—malignant glioma	5.94e-05	0.00997	CbGeAlD
Fluvoxamine—CYP2E1—brain—malignant glioma	5.86e-05	0.00983	CbGeAlD
Fluvoxamine—CYP2D6—central nervous system—malignant glioma	5.84e-05	0.00981	CbGeAlD
Fluvoxamine—ABCB1—medulla oblongata—malignant glioma	5.81e-05	0.00975	CbGeAlD
Fluvoxamine—CYP2D6—cerebellum—malignant glioma	5.71e-05	0.00959	CbGeAlD
Fluvoxamine—ABCB1—midbrain—malignant glioma	5.31e-05	0.00891	CbGeAlD
Fluvoxamine—ABCB1—spinal cord—malignant glioma	5.18e-05	0.0087	CbGeAlD
Fluvoxamine—CYP2D6—brain—malignant glioma	4.64e-05	0.00779	CbGeAlD
Fluvoxamine—ABCB1—central nervous system—malignant glioma	4.2e-05	0.00706	CbGeAlD
Fluvoxamine—ABCB1—cerebellum—malignant glioma	4.11e-05	0.0069	CbGeAlD
Fluvoxamine—ABCB1—brain—malignant glioma	3.34e-05	0.0056	CbGeAlD
Fluvoxamine—CYP1A1—Metabolism—CYP2C18—malignant glioma	1.46e-05	0.000207	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	1.44e-05	0.000204	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—IDH2—malignant glioma	1.44e-05	0.000203	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—BCAN—malignant glioma	1.42e-05	0.000201	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.39e-05	0.000196	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP2B6—malignant glioma	1.38e-05	0.000196	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.38e-05	0.000196	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—COX8A—malignant glioma	1.37e-05	0.000194	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—IDH2—malignant glioma	1.35e-05	0.000191	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP2B6—malignant glioma	1.35e-05	0.000191	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—IDH2—malignant glioma	1.34e-05	0.00019	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	1.32e-05	0.000187	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	1.3e-05	0.000183	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTT1—malignant glioma	1.28e-05	0.000182	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP2B6—malignant glioma	1.27e-05	0.00018	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—IDH1—malignant glioma	1.26e-05	0.000179	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.26e-05	0.000179	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP2B6—malignant glioma	1.26e-05	0.000178	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.26e-05	0.000178	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTT1—malignant glioma	1.26e-05	0.000178	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTT1—malignant glioma	1.25e-05	0.000178	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—IDH1—malignant glioma	1.23e-05	0.000175	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	1.23e-05	0.000175	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	1.22e-05	0.000173	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—SPHK1—malignant glioma	1.22e-05	0.000173	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.21e-05	0.000172	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTP1—malignant glioma	1.2e-05	0.00017	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS1—malignant glioma	1.2e-05	0.00017	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP2C18—malignant glioma	1.2e-05	0.00017	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—SPHK1—malignant glioma	1.19e-05	0.000169	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTT1—malignant glioma	1.18e-05	0.000168	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS1—malignant glioma	1.18e-05	0.000167	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS1—malignant glioma	1.17e-05	0.000166	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CAT—malignant glioma	1.17e-05	0.000166	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP2C18—malignant glioma	1.17e-05	0.000166	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ASMT—malignant glioma	1.17e-05	0.000165	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—IDH1—malignant glioma	1.16e-05	0.000165	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—IDH1—malignant glioma	1.15e-05	0.000163	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—IDH2—malignant glioma	1.15e-05	0.000162	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.13e-05	0.00016	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—SPHK1—malignant glioma	1.13e-05	0.000159	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	1.12e-05	0.000159	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—BCHE—malignant glioma	1.12e-05	0.000158	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—SPHK1—malignant glioma	1.12e-05	0.000158	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS1—malignant glioma	1.11e-05	0.000157	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.11e-05	0.000157	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—NCOR1—malignant glioma	1.1e-05	0.000156	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—SLC5A5—malignant glioma	1.1e-05	0.000156	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP2C18—malignant glioma	1.1e-05	0.000156	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—BCAN—malignant glioma	1.1e-05	0.000155	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—BCHE—malignant glioma	1.09e-05	0.000155	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP2C18—malignant glioma	1.09e-05	0.000155	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—BCHE—malignant glioma	1.09e-05	0.000155	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	1.09e-05	0.000154	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—SLC5A5—malignant glioma	1.08e-05	0.000153	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.08e-05	0.000153	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—SLC5A5—malignant glioma	1.08e-05	0.000153	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2B6—malignant glioma	1.08e-05	0.000153	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—BCHE—malignant glioma	1.03e-05	0.000146	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.03e-05	0.000146	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.03e-05	0.000146	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—SLC5A5—malignant glioma	1.02e-05	0.000144	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	9.94e-06	0.000141	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—IDH1—malignant glioma	9.85e-06	0.000139	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTT1—malignant glioma	9.69e-06	0.000137	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	9.64e-06	0.000136	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	9.55e-06	0.000135	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SPHK1—malignant glioma	9.53e-06	0.000135	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTT1—malignant glioma	9.46e-06	0.000134	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	9.39e-06	0.000133	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2C18—malignant glioma	9.34e-06	0.000132	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	9.18e-06	0.00013	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS1—malignant glioma	9.08e-06	0.000129	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	9.06e-06	0.000128	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	9.05e-06	0.000128	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CAV1—malignant glioma	9.01e-06	0.000128	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTT1—malignant glioma	8.92e-06	0.000126	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTP1—malignant glioma	8.89e-06	0.000126	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS1—malignant glioma	8.87e-06	0.000126	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—IDH2—malignant glioma	8.84e-06	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTT1—malignant glioma	8.84e-06	0.000125	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	8.81e-06	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTP1—malignant glioma	8.71e-06	0.000123	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTP1—malignant glioma	8.69e-06	0.000123	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CAT—malignant glioma	8.65e-06	0.000123	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CAT—malignant glioma	8.48e-06	0.00012	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CAT—malignant glioma	8.46e-06	0.00012	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—BCHE—malignant glioma	8.45e-06	0.00012	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS1—malignant glioma	8.36e-06	0.000118	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—SLC5A5—malignant glioma	8.34e-06	0.000118	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	8.33e-06	0.000118	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2B6—malignant glioma	8.31e-06	0.000118	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS1—malignant glioma	8.28e-06	0.000117	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	8.25e-06	0.000117	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—BCHE—malignant glioma	8.24e-06	0.000117	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTP1—malignant glioma	8.21e-06	0.000116	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CG—malignant glioma	8.2e-06	0.000116	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NCOR1—malignant glioma	8.17e-06	0.000116	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—SLC5A5—malignant glioma	8.14e-06	0.000115	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	8.02e-06	0.000114	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NCOR1—malignant glioma	8e-06	0.000113	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CAT—malignant glioma	7.99e-06	0.000113	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NCOR1—malignant glioma	7.99e-06	0.000113	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PPARG—malignant glioma	7.92e-06	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	7.89e-06	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	7.82e-06	0.000111	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—BCHE—malignant glioma	7.77e-06	0.00011	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	7.74e-06	0.00011	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—BCHE—malignant glioma	7.7e-06	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—SLC5A5—malignant glioma	7.67e-06	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—SLC5A5—malignant glioma	7.61e-06	0.000108	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—IDH1—malignant glioma	7.6e-06	0.000108	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTT1—malignant glioma	7.55e-06	0.000107	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NCOR1—malignant glioma	7.55e-06	0.000107	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	7.5e-06	0.000106	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SPHK1—malignant glioma	7.36e-06	0.000104	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CD—malignant glioma	7.21e-06	0.000102	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2C18—malignant glioma	7.21e-06	0.000102	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	7.19e-06	0.000102	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	7.13e-06	0.000101	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS1—malignant glioma	7.08e-06	0.0001	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	7.05e-06	9.98e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.82e-06	9.65e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTP1—malignant glioma	6.72e-06	9.51e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CAV1—malignant glioma	6.66e-06	9.43e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—BCHE—malignant glioma	6.58e-06	9.32e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTP1—malignant glioma	6.56e-06	9.29e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CAT—malignant glioma	6.54e-06	9.26e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CAV1—malignant glioma	6.52e-06	9.24e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CAV1—malignant glioma	6.51e-06	9.22e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SLC5A5—malignant glioma	6.5e-06	9.2e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CAT—malignant glioma	6.38e-06	9.04e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CB—malignant glioma	6.29e-06	8.9e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTGS2—malignant glioma	6.23e-06	8.82e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.22e-06	8.8e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTP1—malignant glioma	6.18e-06	8.75e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NCOR1—malignant glioma	6.17e-06	8.74e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CAV1—malignant glioma	6.15e-06	8.71e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	6.15e-06	8.7e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTP1—malignant glioma	6.13e-06	8.67e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	6.09e-06	8.62e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CG—malignant glioma	6.07e-06	8.59e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NCOR1—malignant glioma	6.03e-06	8.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CAT—malignant glioma	6.01e-06	8.52e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CAT—malignant glioma	5.96e-06	8.44e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CG—malignant glioma	5.94e-06	8.41e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CG—malignant glioma	5.93e-06	8.4e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.88e-06	8.32e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PPARG—malignant glioma	5.86e-06	8.29e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTT1—malignant glioma	5.83e-06	8.25e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PPARG—malignant glioma	5.74e-06	8.12e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PPARG—malignant glioma	5.72e-06	8.1e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NCOR1—malignant glioma	5.68e-06	8.04e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NCOR1—malignant glioma	5.63e-06	7.97e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CG—malignant glioma	5.6e-06	7.93e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS1—malignant glioma	5.46e-06	7.73e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTEN—malignant glioma	5.43e-06	7.69e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PPARG—malignant glioma	5.41e-06	7.66e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CD—malignant glioma	5.33e-06	7.55e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.31e-06	7.52e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTP1—malignant glioma	5.24e-06	7.41e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CD—malignant glioma	5.22e-06	7.4e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CD—malignant glioma	5.21e-06	7.38e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CAT—malignant glioma	5.09e-06	7.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—BCHE—malignant glioma	5.08e-06	7.19e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CAV1—malignant glioma	5.03e-06	7.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SLC5A5—malignant glioma	5.02e-06	7.1e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CD—malignant glioma	4.93e-06	6.97e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CAV1—malignant glioma	4.91e-06	6.96e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NCOR1—malignant glioma	4.81e-06	6.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.81e-06	6.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CB—malignant glioma	4.65e-06	6.58e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CAV1—malignant glioma	4.63e-06	6.56e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS2—malignant glioma	4.61e-06	6.52e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CAV1—malignant glioma	4.59e-06	6.5e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CG—malignant glioma	4.59e-06	6.49e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CB—malignant glioma	4.55e-06	6.45e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CB—malignant glioma	4.54e-06	6.43e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS2—malignant glioma	4.51e-06	6.39e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS2—malignant glioma	4.5e-06	6.38e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CG—malignant glioma	4.48e-06	6.34e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PPARG—malignant glioma	4.43e-06	6.27e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.38e-06	6.21e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PPARG—malignant glioma	4.32e-06	6.12e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CB—malignant glioma	4.29e-06	6.08e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS2—malignant glioma	4.25e-06	6.02e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CG—malignant glioma	4.22e-06	5.97e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CG—malignant glioma	4.18e-06	5.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PPARG—malignant glioma	4.07e-06	5.76e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTP1—malignant glioma	4.04e-06	5.72e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PPARG—malignant glioma	4.03e-06	5.71e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CD—malignant glioma	4.03e-06	5.71e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTEN—malignant glioma	4.02e-06	5.69e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTEN—malignant glioma	3.93e-06	5.57e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CD—malignant glioma	3.93e-06	5.57e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CAT—malignant glioma	3.93e-06	5.57e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTEN—malignant glioma	3.93e-06	5.56e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CAV1—malignant glioma	3.92e-06	5.55e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CA—malignant glioma	3.83e-06	5.43e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.75e-06	5.31e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NCOR1—malignant glioma	3.71e-06	5.26e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTEN—malignant glioma	3.71e-06	5.25e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CD—malignant glioma	3.71e-06	5.25e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CD—malignant glioma	3.68e-06	5.2e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CG—malignant glioma	3.57e-06	5.06e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CB—malignant glioma	3.51e-06	4.97e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS2—malignant glioma	3.48e-06	4.93e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PPARG—malignant glioma	3.45e-06	4.88e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CB—malignant glioma	3.43e-06	4.86e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS2—malignant glioma	3.4e-06	4.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CB—malignant glioma	3.23e-06	4.58e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CB—malignant glioma	3.2e-06	4.54e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS2—malignant glioma	3.2e-06	4.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS2—malignant glioma	3.17e-06	4.49e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CD—malignant glioma	3.14e-06	4.45e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—AKT1—malignant glioma	3.13e-06	4.43e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTEN—malignant glioma	3.04e-06	4.3e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CAV1—malignant glioma	3.03e-06	4.29e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTEN—malignant glioma	2.96e-06	4.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CA—malignant glioma	2.83e-06	4.01e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTEN—malignant glioma	2.79e-06	3.95e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CA—malignant glioma	2.78e-06	3.93e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CA—malignant glioma	2.77e-06	3.92e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTEN—malignant glioma	2.77e-06	3.92e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.76e-06	3.9e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CB—malignant glioma	2.74e-06	3.88e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS2—malignant glioma	2.71e-06	3.84e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PPARG—malignant glioma	2.66e-06	3.77e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CA—malignant glioma	2.62e-06	3.71e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.42e-06	3.43e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTEN—malignant glioma	2.37e-06	3.35e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—AKT1—malignant glioma	2.32e-06	3.28e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—AKT1—malignant glioma	2.27e-06	3.21e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—AKT1—malignant glioma	2.26e-06	3.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CA—malignant glioma	2.14e-06	3.03e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—AKT1—malignant glioma	2.14e-06	3.03e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.11e-06	2.99e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS2—malignant glioma	2.09e-06	2.96e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CA—malignant glioma	2.09e-06	2.96e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.97e-06	2.79e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CA—malignant glioma	1.95e-06	2.76e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTEN—malignant glioma	1.83e-06	2.58e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—AKT1—malignant glioma	1.75e-06	2.48e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—AKT1—malignant glioma	1.71e-06	2.42e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.67e-06	2.36e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—AKT1—malignant glioma	1.61e-06	2.28e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—AKT1—malignant glioma	1.6e-06	2.26e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—AKT1—malignant glioma	1.36e-06	1.93e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.29e-06	1.82e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—AKT1—malignant glioma	1.05e-06	1.49e-05	CbGpPWpGaD
